Table 4.

Multivariate Cox proportional hazards model results for progression-free and overall survival for patients with stage III uterine carcinosarcoma.

Variable	Progression-free survival		Overall survival
	HR (95% CI)	p-value	HR (95% CI)	p-value
Multimodal therapy vs. chemotherapy alone	0.58 (0.27–1.25)	0.17	0.51 (0.22–1.16)	0.10
Radiation therapy vs. chemotherapy alone	0.95 (0.36–2.50)	0.91	1.19 (0.42–3.38)	0.74
Observation alone vs. Chemotherapy alone	2.41 (1.16–5.21)	0.03	2.40 (1.03–5.56)	0.04
Site 4 vs. Site 1	6.15 (1.70–22.32)	0.01	4.61 (1.03–20.63)	0.05
Site 3 vs. Site 1	1.61 (0.72–3.59)	0.25	1.52 (0.61–3.79)	0.37
Site 2 vs. Site 1	1.82 (0.67–4.96)	0.24	1.83 (0.91–5.49)	0.28
Race (White vs. Black)	0.66 (0.34–1.28)	0.22	0.56 (0.27–1.19)	0.13
Cancer history (Yes vs. No)	1.31 (0.63–2.70)	0.47	1.75 (0.76–4.07)	0.19
Residual disease (Yes vs. No)	1.72 (0.78–3.80)	0.18	1.69 (0.70–4.08)	0.25
LVSI (Yes vs. No)	2.56 (1.11–5.89)	0.03	3.82 (1.41–10.38)	0.01
Stage IIIC vs. IIIA	2.78 (1.38–5.61)	0.004	2.89 (1.30–6.43)	0.01
Stage IIIB vs. IIIA	0.52 (0.06–4.14)	0.53	0.44 (0.04–4.37)	0.48
Age (continuous)	1.00 (0.97–1.03)	0.98	1.00 (0.96–1.03)	0.95
Year of diagnosis (continuous)	1.02 (0.95–1.10)	0.60	1.04 (0.95–1.13)	0.43
Parity (continuous)	1.02 (0.86–1.21)	0.82	1.00 (0.83–1.21)	0.98